Mediar Therapeutics CEO Rahul Ballal (L) and CSO Paul Yaworsky

Five phar­mas back $85M Se­ries A for Me­di­ar's fi­bro­sis-mod­u­lat­ing an­ti­bod­ies

Me­di­ar Ther­a­peu­tics nabbed $85 mil­lion to get in the clin­ic next year with its first an­ti­body meant to mod­u­late fi­bro­sis, hence the biotech’s name …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.